GlassScriptPhysician profile
Adam Robert Ford
NPI 1326508946
$7,757.82
in general payments reported to CMS, 2019-2025
32 companies · $3,089 in 2025
The $3,089 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.07 · 2022: $277 · 2023: $1,047 · 2024: $3,261 · 2025: $3,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,157 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,156.79 |
| Education | $239.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.65 | 2023-2025 | |
| Lilly USA, LLC | $698.43 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $669.06 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $609.73 | 2022-2025 | Dupixent |
| Incyte Corporation | $480.62 | 2023-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $447.56 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Biotech, INC. | $446.27 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $404.84 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $396.68 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $296.67 | 2023-2025 | Cabtreo, Siliq, Jublia |
| Pfizer INC. | $293.42 | 2024-2025 | |
| Dermavant Sciences, INC. | $261.38 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $245.81 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $236.28 | 2024-2025 | |
| Merz North America, INC. | $192.53 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $173.08 | 2024-2025 | Zoryve |
| Biofrontera INC. | $138.42 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Leo Pharma INC. | $137.87 | 2025 | Adbry, Anzupgo |
| Abiomed | $124.51 | 2023 | Impella |
| Genentech USA, INC. | $84.07 | 2019 | |
| Abbott Laboratories | $78.20 | 2023 | Ensite |
| Organon LLC | $70.47 | 2024-2025 | Vtama |
| Verrica Pharmaceuticals INC. | $61.47 | 2024-2025 | Ycanth |
| Amgen INC. | $56.60 | 2024 | Otezla |
| Botanix Sb INC | $47.28 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $45.86 | 2025 | Nemluvio |
| Almirall LLC | $36.03 | 2024-2025 | Klisyri |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Organogenesis INC. | $23.59 | 2024 | Puraply Am |
| Strata Skin Sciences, INC. | $21.63 | 2024 | Xtrac |
| Polynovo North America LLC | $18.14 | 2024 | Novosorb Btm |
| Lnhc, INC | $14.50 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.